FY2026 Earnings Forecast for Arvinas Issued By HC Wainwright

Key Points

• HC Wainwright forecasts Arvinas will break even in FY2026 at $0.00 EPS and maintains a Buy rating with a $13 price target.
• Arvinas reported a quarterly loss of $0.82 per share, better than analysts expected, but revenue was only $0.5 million versus a $12.39 million estimate and fell 98.8% year over year.
• HC Wainwright projects continued losses from 2027 through 2030, including a $2.44-per-share loss in 2027, highlighting the company’s ongoing profitability risk.

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Equities research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for Arvinas in a report released on Tuesday, November 3rd. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings of $0.00 per share for the year. HC Wainwright has a "Buy" rating and a $13.00 price objective on the stock. The consensus estimate for Arvinas' current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Arvinas' Q4 2026 earnings at ($0.88) EPS, Q1 2027 earnings at ($0.55) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.63) EPS, Q4 2027 earnings at ($0.67) EPS, FY2027 earnings at ($2.44) EPS, FY2028 earnings at ($2.70) EPS, FY2029 earnings at ($1.74) EPS and FY2030 earnings at ($0.72) EPS.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.10. Arvinas had a negative return on equity of 2.06% and a negative net margin of 3.45%. The business had revenue of $0.50 million for the quarter, compared to analysts' expectations of $12.39 million. During the same quarter in the prior year, the business earned ($0.48) EPS. The firm's revenue for the quarter was down 98.8% on a year-over-year basis.

A number of other research firms have also recently issued reports on ARVN. Morgan Stanley set a $10.00 target price on shares of Arvinas in a research note on Monday, August 10th. Weiss Ratings cut shares of Arvinas from a "sell (d+)" rating to a "sell (d)" rating in a report on Friday, October 23rd. Wells Fargo & Company cut shares of Arvinas from an "overweight" rating to an "equal weight" rating and lowered their price target for the company from $15.00 to $11.00 in a report on Tuesday, August 4th. Wedbush raised their price objective on shares of Arvinas from $11.00 to $12.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 5th. Finally, Zacks Research upgraded Arvinas from a "hold" rating to a "strong-buy" rating in a report on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $15.18.

Arvinas Price Performance

NASDAQ:ARVN opened at $7.42 on Thursday. Arvinas has a one year low of $6.74 and a one year high of $14.51. The company has a market cap of $478.75 million, a P/E ratio of -30.92 and a beta of 1.81. The firm's fifty day moving average price is $7.98 and its two-hundred day moving average price is $9.63.

Institutional Investors Weigh In On Arvinas

Institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Arvinas in the third quarter valued at approximately $26,000. Integrated Wealth Concepts LLC acquired a new stake in Arvinas during the second quarter worth approximately $48,000. Pinnacle Wealth Planning Services Inc. acquired a new stake in Arvinas during the third quarter worth approximately $45,000. Quantbot Technologies LP acquired a new stake in Arvinas during the second quarter worth approximately $85,000. Finally, Corient Private Wealth LP bought a new position in Arvinas during the 2nd quarter worth $95,000. Institutional investors own 95.19% of the company's stock.

Key Headlines Impacting Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, implying about 75% upside from the cited $7.42 share price. Arvinas Stock Picked Up by Analysts at HC Wainwright
• Neutral Sentiment: Arvinas plans to present preliminary Phase 1 data for ARV-393 at the 2026 American Society of Hematology meeting. The presentation could provide a clinical catalyst, though the report does not disclose results yet. Arvinas to Present Preliminary ARV-393 Clinical Data
• Negative Sentiment: Recent quarterly results showed revenue of just $0.5 million, far below the $12.39 million analyst estimate and down 98.8% year over year. The $0.82-per-share loss was better than the consensus loss estimate, but wider than the year-ago loss. Arvinas Reports Third Quarter 2026 Results
• Negative Sentiment: HC Wainwright’s estimates anticipate losses in 2027–2030, including a $2.44-per-share loss in 2027, underscoring the company’s ongoing path to profitability risk despite the bullish rating.

Arvinas Company Profile

Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company's proprietary PROTAC® protein degrader platform is designed to direct the body's natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.